A Review on: Phase ‘0’ Clinical Trials or Exploratory Investigational New Drug
Journal Title: Turkish Journal of Pharmaceutical Sciences - Year 2017, Vol 14, Issue 1
Abstract
In a move to speed up the development of new medicines, the Food and Drug Administration announced in January 2006 the creation of the exploratory Investigational New Drug (IND), the so-called phase ‘0’ clinical trials. This guidance is intended to clarify what preclinical and clinical approaches, as well as chemistry, manufacturing, and controls information, should be considered when planning exploratory studies in humans, including studies of closely related drugs or therapeutic biological products, under an IND application (21 CFR 312). Existing regulations allow a great deal of flexibility in the amount of data that needs to be submitted with an IND application, depending on the goals of the proposed investigation, the specific human testing proposed, and the expected risks. The agency believes that sponsors have not taken full advantage of that flexibility and often provide more supporting information in INDs than is required by regulations. This guidance is intended to clarify what manufacturing controls, preclinical testing, and clinical approaches can be considered when planning limited, early exploratory IND studies in humans.
Authors and Affiliations
Ashish A. GAWAI, Faisal SHAIKH, Mangesh GADEKAR, Nitin DEOKAR, Shivanand KOLHE, K. R. BIYANI
Keywords
Related Articles
- EP ID EP380914
- DOI 10.4274/tjps.63935
- Views 159
- Downloads 0
Histopathology Study of Alginate Microspheres Containing Ovalbumin on Liver and Kidney Following Oral Administration and Evaluation of Uptake by Peyer’s Plaque
Objectives: The development of oral vaccine formulations has been widely investigated to overcome oral route problems. This research investigated the in vivo immune response of ovalbumin-alginate microspheres by uptake c...
Spectrophotometric Quantification of Anti-inflammatory Drugs by Application of Chromogenic Reagents
Objectives: Simple, specific, accurate, precise, sensitive, and cost effective spectrophotometric methods were developed and validated for quantification of the drugs lornoxicam (LOR) and mesalamine (MES) in pure form an...
Enhancement of Dissolution of Fenofibrate Using Complexation with Hydroxy Propyl β-Cyclodextrin
Objectives: The aim of the present study was to enhance the dissolution rate of fenofibrate using complexation with hydroxy propyl β-cyclodextrin (HPβCD). Materials and Methods: The phase solubility behavior of fenofibra...
Development of Nanocochleates Containing Erlotinib HCl and Dexketoprofen Trometamol and Evaluation of In Vitro Characteristic Properties
Objectives: Erlotinib HCI is a tyrosine kinase receptor inhibitor and an anticancer agent that was first approved by the FDA in 2004 for treatment of non-small-cell lung cancer and pancreatic cancer. Dexketoprofen tromet...
Pharmacological and Toxicological Properties of Eugenol
Eugenol is a volatile phenolic constituent of clove essential oil obtained from Eugenia caryophyllata buds and leaves. It is a functional ingredient of numerous products which have been used in the pharmaceutical, food a...